What medication can be given to induce menstruation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medications to Induce Menstruation

For inducing menstruation in women with amenorrhea, norethindrone acetate at doses of 5-10 mg daily for 5-10 days is the most effective medication to produce withdrawal bleeding within 3-7 days after discontinuation. 1

Medication Options Based on Clinical Context

Primary Option: Progestins

  • Norethindrone acetate: 5-10 mg daily for 5-10 days is FDA-approved specifically for inducing withdrawal bleeding in women with secondary amenorrhea 1
  • Medroxyprogesterone acetate (MPA): 10 mg daily for 10-14 days can be used as an alternative to induce withdrawal bleeding 2
  • Micronized progesterone (MP): 200 mg daily orally or vaginally for 12-14 days can also effectively induce withdrawal bleeding 2

Secondary Options

  • Combined oral contraceptives (COCs): Effective for treating amenorrhea, particularly in women using DMPA (depot medroxyprogesterone acetate) 2, 3
  • 17β-estradiol (17βE) with progestin: Can be administered in sequential regimens to induce withdrawal bleeding 2

Clinical Algorithm for Inducing Menstruation

For Secondary Amenorrhea or Hormonal Imbalance

  1. First-line therapy: Norethindrone acetate 5-10 mg daily for 5-10 days 1

    • Withdrawal bleeding typically occurs within 3-7 days after discontinuation
    • Adequate endometrial priming with either endogenous or exogenous estrogen is necessary for optimal results
  2. Alternative approach: Medroxyprogesterone acetate 10 mg daily for 12-14 days 2

    • Particularly useful when planning cyclic withdrawal bleeding
  3. For women with amenorrhea on DMPA contraception:

    • Low-dose combined oral contraceptives can effectively re-induce menstrual bleeding 3
    • 70% of women receiving COCs experience return of menstrual bleeding compared to only 22.7% with placebo 3

For Dysfunctional Uterine Bleeding Requiring Prompt Control

  • Higher doses of MPA (60-120 mg initially, followed by 20 mg daily for 10 days) can rapidly control excessive bleeding 4
  • This approach is particularly effective in adolescents with dysfunctional uterine bleeding 4

Important Clinical Considerations

  • Confirm absence of pregnancy before initiating any hormonal therapy to induce menstruation 2
  • Rule out underlying pathology as the cause of amenorrhea before attributing it to hormonal imbalance 1
  • For women with premature ovarian insufficiency (POI), sequential hormone therapy with estrogen followed by progestin is preferred over progestin-only regimens 2
  • For women desiring contraception, combined hormonal contraceptives can both provide contraception and regulate menstrual cycles 2

Monitoring and Follow-up

  • Withdrawal bleeding should occur within 3-7 days after discontinuing progestin therapy 1
  • If no bleeding occurs after progestin challenge, consider:
    • Insufficient endometrial priming (may need estrogen priming first)
    • Outflow tract obstruction
    • Endometrial damage (Asherman's syndrome)
    • Severe hypoestrogenism 2

Potential Side Effects and Precautions

  • Common side effects of progestin therapy include:
    • Headaches
    • Breast tenderness
    • Mood changes 2
  • For women with recurrent episodes of abnormal uterine bleeding, planned menstrual cycling with norethindrone acetate may be beneficial 1
  • Avoid progestins with anti-androgenic effects in women with iatrogenic POI, as they may worsen hypoandrogenism 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Low-dose oral contraceptive to re-induce menstrual bleeding in amenorrheic women on DMPA treatment: a randomized clinical trial.

Medical science monitor : international medical journal of experimental and clinical research, 2006

Research

High-dose medroxyprogesterone acetate for the treatment of dysfunctional uterine bleeding in 24 adolescents.

The Australian & New Zealand journal of obstetrics & gynaecology, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.